Variagenics and Boehringer in pharmacogenomics deal

VGNX will use its Variagenic Impact Program to perform custom SNP discovery on an undisclosed therapeutic candidate from Boehringer Ingelheim Pharmaceuticals (Ridgefield, Conn.) in order to identify g...